journal article·2011Open access

Immunohistochemical detection of p53 and PCNA in ameloblastoma and adenomatoid odontogenic tumor

Jahanshah Salehinejad, Reza Zare-Mahmoodabadi, Shadi Saghafi, Amir-Hossien Jafarian, Narges Ghazi, Ali-Reza Rajaei, Parviz Marouzi

Journal of Oral Science· Volume 53· Issue 2

Abstract

Although ameloblastoma and adenomatoid odontogenic tumor (AOT) belong to the same group according to the World Health Organization, they show different biologic behaviors. PCNA, an amplifier of cell proliferation, and p53, a tumor suppressor protein, are overexpressed in some odontogenic lesions. The purpose of this study was to immunohistochemically evaluate the expression of p53 and PCNA to clarify the possible role of these proteins in different behaviors of ameloblastoma and AOT. The immunohistochemical expression of PCNA and p53 was determined in 30 solid ameloblastomas and 12 AOTs. Statistical tests including one-way ANOVA, t-test, chi-square, Mann-Whitney U and Kendall were used to analyze the data. All tissue sections (except one specimen of plexiform ameloblastoma) exhibited immunoexpression for p53. PCNA was expressed in all specimens. There was no significant difference in PCNA expression between ameloblastomas and AOTs (P > 0.05). For p53, there was no statistical difference between subtypes of ameloblastomas (P > 0.05), whereas statistical differences were observed between ameloblastomas and AOTs (P < 0.001). There was no statistical difference in PCNA intensity of staining between ameloblastomas and AOTs (P > 0.05), whereas the p53 intensity in ameloblastomas was stronger than AOTs (P < 0.05). Positive correlation between PCNA and p53 was observed. We concluded that PCNA overexpression is not responsible for the difference in clinical behavior of these two lesions, whereas the expression of p53 in ameloblastoma may explain the more aggressive nature of this tumor compared with AOT.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Oral and Maxillofacial Pathology · Bone Tumor Diagnosis and Treatments · dental development and anomalies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (27)

Show source-provided references
1. 1. Neville BW, Damm DD, Allen CM, Bouquot JE (2009) Oral and maxillofacial pathology. 3rd ed, Saunders, Philadelphia, 701-715.
2. 10.1038/modpathol.380014710.1038/modpathol.3800147 ↗
3. 3. Migaldi M, Sartori G, Rossi G, Cittadini A, Sgambato A (2008) Tumor cell proliferation and microsatellite alterations in human ameloblastoma. Oral Oncol 44, 50-60.10.1016/j.oraloncology.2006.12.004 ↗
4. 4. Cawson RA, Binne WH, Barrett AW, Wright JM (2001) Oral disease: clinical and pathological correlations. 3rd ed, Mosby, London, 52-68.
5. 5. Gnepp DR (2008) Diagnostic surgical pathology of the head and neck. 2nd ed, Saunders, Philadelphia, 616-623.
6. 10.1016/S1368-8375(01)00036-710.1016/S1368-8375(01)00036-7 ↗
7. 10.1016/0092-8674(89)90045-710.1016/0092-8674(89)90045-7 ↗
8. 8. Kumar V, Cotran RS, Robbins SL (2003) Robbins basic pathology. 7th ed, Saunders, Philadelphia, 270-304.
9. 10.1111/j.0904-2512.2004.00044.x10.1111/j.0904-2512.2004.00044.x ↗
10. 10. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weslon A, Modali R, Harris CC, Vogelstein B (1989) Mutation in the p53 gene occur in diverse human tumour types. Nature 342, 705-708.10.1038/342705a0 ↗
11. 10.1101/gad.10.9.105410.1101/gad.10.9.1054 ↗
12. 12. Furihata M, Sonobe H, Ohtsuki Y, Yamashita M, Morioka M, Yamamoto A, Terao N, Kuwahara M, Fujisaki N (1996) Detection of p53 and bcl-2 protein in carcinoma of the renal pelvis and ureter including dysplasia. J Pathol 178, 133-139.10.1002/(SICI)1096-9896(199602)178:2<133::AID-PATH455>3.0.CO;2-F ↗
13. 13. Levine AJ, Momand J, Finlay CA (1991) The p53 tomour suppressor gene. Nature 351, 453-456.10.1038/351453a0 ↗
14. 14. Fujita S, Seki S, Fujiwara M, Ikeda T (2008) Midkine expression correlating with growth activity and tooth morphogenesis in odontogenic tumors. Hum Pathol 39, 694-700.10.1016/j.humpath.2007.09.014 ↗
15. 15. Barboza CA, Pereira Pinto L, Freitas Rde A, Costa Ade L, Souza LB (2005) Proliferating cell nuclear antigen (PCNA) and p53 protein expression in ameloblastoma and adenomatoid odontogenic tumor. Braz Dent J 16, 56-61.10.1590/S0103-64402005000100010 ↗
16. 16. Al-Salihi KA, Li LY, Azlina A (2006) p53 gene mutation and protein expression in ameloblastomas. Braz J Oral Sci 5, 1034-1040.
17. 10.1007/s10006-004-0539-710.1007/s10006-004-0539-7 ↗
18. 10.1111/j.1600-0714.1995.tb01207.x10.1111/j.1600-0714.1995.tb01207.x ↗
19. 19. El-Sissy NA (1999) Immunohistochemical detection of p53 protein in ameloblastoma types. East Mediterr Health J 5, 478-489.10.26719/1999.5.3.478 ↗
20. 20. Regezi JA, Sciubba JJ, Jordan RCK (2008) Oral pathology: clinical pathologic correlations. 5th ed, Saunders, St Louis, 261-270.
21. 21. Moghadam BKH, Yazdi I, Barker B, Cob C, Cumming CG (1997) Immunohistochemical determination of tumor-associated antigens in ameloblastoma and odontogenic cysts. Acta Med Iran 35, 1-7.
22. 10.1016/0964-1955(94)00046-710.1016/0964-1955(94)00046-7 ↗
23. 10.1016/0964-1955(96)00007-310.1016/0964-1955(96)00007-3 ↗
24. 10.1034/j.1600-0714.2001.300509.x10.1034/j.1600-0714.2001.300509.x ↗
25. 25. Ueno S, Mushimoto K, Shirasu R (1989) Prognostic evaluation of ameloblastoma based on histologic and radiographic typing. J Oral Maxillofac Surg 47, 11-15.10.1016/0278-2391(89)90116-X ↗
26. 10.1016/0964-1955(94)00037-510.1016/0964-1955(94)00037-5 ↗
27. 10.2334/josnusd.52.60910.2334/josnusd.52.609 ↗